Application of a Mathematical Model to the Study of RES Phagocytosis in Mice
A mathematical model of RES phagocytic function has been developed. Data obtained using this model are compatible with results obtained from animal experimentation. Following administration of a large dose of colloidal carbon, the clearance observed in the “blood” is initially zero order, gradually changing to first order as the concentration in “blood” decreases. It may therefore be invalid to accept the previous conclusions that colloid clearance follows first-order kinetics, with rate constants that are dependent upon initial concentration. Short segments of model clearance curves may appear to be first order when in fact they may be zero order.
Analysis of model behavior suggests that at low and intermediate concentrations of carbon the RES does not exhibit its maximal functional capacity. By using high doses of carbon, however, the maximum functional capacity of the RES is measured. The effect of radiation on the maximum functional capacity of the RES in CD-1 mice was tested. 137Cs gamma radiation (LD05/30) decreased the phagocytic capacity of the RES by approximately 13%. Experiments with puromycin suggest that protein synthesis does not limit the functional capacity of the RES. Doses of puromycin that profoundly decreased protein synthesis were without effect on phagocytosis.
KeywordsPhagocytic Function Semilogarithmic Plot Clearance Curve Saturate Dose Colloid Concentration
Unable to display preview. Download preview PDF.
- 1.G. Biozzi, B. Benacerraf, and B. N. Halpern, Brit. J. Exptl. Pathol., 34: 441, 1953.Google Scholar
- 2.G. Biozzi and C. Stiffel, in: H. Popper and F. Schnaffiner, Eds., Progress in Liver Diseases, New York, Grune and Stratton Inc., 1965, p. 166.Google Scholar
- 3.R. K. Fred, J. G. Harris, and M. L. Shore, J. Reticuloendothelial Soc., 2: 344, 1965. (Abstract) Full text to be published.Google Scholar
- 5.E. R. Gabrieli. and F.M. Snell, J. Reticuloendothelial Soc., 2: 141, 1965Google Scholar
- 6.T.M. Saba and N.H. Di Luzio, J. Reticuloendothelial Soc., 2: 437, 1965.Google Scholar
- 10.J. P. Filkins, R. E. Chase, and J.J. Smith, J. Reticuloendothelial Soc., 2: 287, 1965.Google Scholar
- 12.E. L. Dobson, in: B.N. Halpern, B. Benacerraf, and J.F. Delafres-naye, Eds., Physiopathology of the Reticuloendothelial System: A Symposium, Oxford, Blackwell Scientific Publications, 1955, p. 80.Google Scholar
- 13.B. Benacerraf, G. Biozzi, A. Cuendet, and B.N. Halpern, J. Physiol., 128: 10, 1955.Google Scholar
- 15.S.J. Riggi and N. R. Di Luzio, Am. J. Physiol., 200: 297, 1961.Google Scholar
- 16.Gunther—Wagner Pelikan Ink Works, Hanover, Germany.Google Scholar
- 17.B. N. Halpern, B. Benacerraf, and G. Biozzi, Brit. J. Exptl. Pathol., 34: 426, 1953.Google Scholar
- 19.Puromycin Dihydrochloride, M.W. 544.5, M.P. 175-177°, Nutritional Biochemicals Corp., Cleveland, Ohio, Refs.: (i) Waller et al., J.Am. Chem. Soc., 75: 2025, 1953, (ii) Porter et al., Antibiot. Chemotherapy, 2: 409, 1952.Google Scholar
- 20.L-Leucine—C14 (uniformly labeled), 1.7 me/mg, Lot No. 190-117c-46, New England Nuclear Corporation, Boston, Mass.Google Scholar
- 21.Hydroxide of Hyamine* R 10-x, p-(diisobutyl-cresoxyethoxyethyl) dimethylbenzylammonium hydroxide, 1 molar in methanol, Lot No. 1193, Packard Instrument Co., Inc., LaGrange, Ill.Google Scholar
- 23.F.N Hayes, in: S. Rothchild, Ed., Advances in Tracer Methodolog Vol. 3, New York, Plenum Press, 1966, p. 81.Google Scholar
- 26.Glucan, Lot No. IF 5500, Fleischmann Laboratories, Division of Standard Brands, Inc., Stamford, Conn.Google Scholar
- 27.S. typhosa endotoxin (DiFco). Kindly furnished by Dr. W. W. Smith, National Cancer Institute, Bethesda, Md.Google Scholar
- 29.E.L. Dobson, L.S. Kelly, and C.R. Finney, The Physiologist, 3: 50, 1960.Google Scholar
- 30.R.W. Brauer, in: R.W. Brauer, Ed., Liver Function, Washington, D. C., American Institute of Biological Sciences, 1958, p. 113.Google Scholar